Abstract: A process for purifying a dicarboxylic acid that is derived from the mixed oxidation products from an ozonization of a mixture containing an ethylenically unsaturated compound having between 6 to 24 carbons, the process includes distilling the mixed oxidation products to provide a first distillate, and a second distillate, where the second distillate includes the dicarboxylic acid and impurity acids, partitioning the second distillate between water and a organic solvent, separating the organic solvent layer from the water layer, lowering the temperature of the water layer to crystallize at least a portion of the dicarboxylic acid, separating the crystallized dicarboxylic acid solid, melting the crystallized dicarboxylic acid, and distilling the liquid dicarboxylic acid to provide a purified dicarboxylic acid.

Abstract: In various embodiments, the present disclosure describes fullerene derivatives that are capable of photocatalytically generating reactive oxygen species in the presence of ultraviolet and/or visible light. In some embodiments, the fullerene derivatives are aminofullerenes containing a plurality of amine-terminated moieties covalently bonded to the fullerene cage. The fullerene derivatives may optionally be covalently bonded to a substrate surface for use in photocatalytic disinfection systems for removing various contaminants including, for example, bacteria, viruses, protozoa and chemical pollutants. Methods using the present fullerene and aminofullerene derivatives in various purification processes are also described herein.

Abstract: The present invention relates to a recombinant eukaryotic cell selected from a yeast of a filamentous fungus comprising a nucleotide sequence encoding a NAD(H)-dependent fumarate reductase that catalyses the conversion of fumaric acid to succinic acid. The invention further relates to a process for the production of succinic acid wherein the eukaryotic cell according to the present invention is used.

Abstract: The invention relates to the use of radical traps in detergents and cleaners in order to improve cleaning performance, in particular for dirt containing polymerizable dyes.

Abstract: Processes for making monoammonium succinate (MAS) and/or succinic acid (SA) from either a clarified diammonium succinate (DAS)-containing fermentation broth or a clarified MAS-containing fermentation broth include (a) distilling the broth to form an overhead that includes water and optionally ammonia and a liquid bottoms that includes MAS or SA; (b) cooling and/or evaporating the bottoms and optionally adding an antisolvent to the bottoms to attain a temperature and composition sufficient to cause the bottoms to produce a solid portion that contains MAS or SA in contact with a liquid portion; (c) separating the solid portion from the liquid portion; and (d) recovering the solid portion.

Abstract: The present invention relates to an economic process for preparing surface-reacted calcium carbonate. The present invention further relates to a surface-reacted calcium carbonate having an increased specific BET surface area, and the use of a process for adjusting the specific BET surface area.

Abstract: An improved process for preparing ammonium salts from fumaric or succinic acid, is described. The method consists of neutralizing the corresponding acid carbonate or ammonium bicarbonate at a molar stoichiometric or greater than the stoichiometric ratio of 4-5% in a saturated aqueous solution of the synthesized salt at a temperature not exceeding 40° C., followed by separation of the product and drying at a temperature not exceeding 70° C. After separation of the ammonium salts, the filtrate can be re-used. Isolation of the product is usually carried out by cooling the reaction mixture to a temperature of 15-18C°. The product comes out in almost crystalline form. Saturated aqueous solution of the synthesized salt is formed by the interaction of carbonate or ammonium bicarbonate with the appropriate acid at a temperature not exceeding 40° C. It is possible to obtain cleaner salt concentration weighing more than 99% and not yielding lower than 98%.

Abstract: A new method for preparing salts of metal cations and organic acids, especially divalent salts of alkaline earth metal ions from group II of the periodic system and carboxylic acids. The method comprising the use of a high temperature (about 90° or more) and, optionally. high pressure, in order to obtain a higher yield, purity and faster reaction speed than obtained with known synthesis methods. In particular, the present invention relates to the production of strontium salts of carboxylic acids. Novel strontium salts are also provided by the present method.

Abstract: Herein are disclosed adducts of amines and polycarboxylic acids, and methods of making such adducts. Such adducts can be used to remove cyanogen chloride. Also disclosed are methods of providing such adducts on supports to form filter media. Also disclosed are methods of combining such filter media with catalysts and/or with porous polymeric webs to form filter systems.

Abstract: An absorbent core for an absorbent article comprising from 1 to 2000 mg of a not cross linked polycarboxylic acid based polymer having an average molecular weight between 1000 and 25000 Da.

Abstract: A diesel fuel additive composition, a fuel containing the fuel additive, a method for improving diesel engine performance using the additive. The diesel fuel additive includes a reaction product of (a) a hydrocarbyl-substituted acylating agent and (b) a reactant selected from the group consisting of a nitrogen-containing compound, a hydroxyl-containing compound, and water that provides a reaction product selected from the group consisting (1) a mono-amide/mono-acid or metal free mono-acid salt thereof, (2) a diacid or metal free diacid salt thereof, and (3) mono-ester/mono-acid or metal free mono-acid salt thereof. The reaction product includes at least about 10 molar percent acid groups based on total moles of the reaction product.

Abstract: A composition of an oil-soluble ionic detergent that does not contribute metal ions to the composition, and which comprises a quaternary non-metallic pnictogen cation and an organic anion having at least one hydrocarbyl group of sufficient length to impart oil solubility to the detergent, the detergent having a total base number (TBN) to total acid number (TAN) ratio of at least 2:1 imparts ash-free basicity to a lubricant composition.

Abstract: The subject invention provides deuterated rasagiline, its salts and uses.

Abstract: A process for preparing 2,3-di(non-linear-alkyl)-2-cyanosuccinate compounds, especially 2,3-diisopropyl-2-cyanosuccinate compounds, and processes for preparing 2,3-di(non-linear-alkyl)succinic acids and esters thereof by using the 2,3-di-non-linear propyl-2-cyanosuccinate compounds as intermediates are disclosed.

Abstract: Hydrocarbon-based compounds containing at least one nitrile function are converted into compounds containing at least one carboxylic function, and into ester compounds from the carboxylic compounds thus obtained; such conversion entails reacting the nitrile compound with a hydroxyl basic compound in solution in a solvent at a temperature of between 80 and 150° C., in eliminating the ammonia formed, in reacting the salt obtained with a mineral acid, and then in recovering the compound containing at least one carboxylic function and, optionally, esterifying the acids obtained by reaction with an alcohol.

Abstract: A coalescent composition for coating compositions such as paints, adhesives, and coatings comprising a blend of dibasic esters, specifically (i) esters of adipic, glutaric, and/or succinic diacids and/or (ii) esters of isomers of adipic acid have advantages, including efficiency and low VOC.

Abstract: The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.

Abstract: A method comprising providing a starting composition comprising a polyunsaturated fatty acid, a polyunsaturated fatty ester, a carboxylate salt of a polyunsaturated fatty acid, a polyunsaturated triglyceride, or a mixture thereof; self-metathesizing the starting composition or cross-metathesizing the starting composition with at least one short-chain olefin in the presence of a metathesis catalyst to form self-/cross-metathesis products comprising: cyclohexadiene; at least one olefin; and one or more acid-, ester-, or salt-functionalized alkene; and reacting cyclohexadiene to produce at least one cycloalkane or cycloalkane derivatives.

Abstract: A method of improving flowability of adipic acid includes adding to the adipic acid at a relatively low temperature a flowability improving agent, such as an acyclic saturated monobasic acid containing 10 to 22 carbon atoms or an acyclic saturated dibasic acid containing 10 to 14 carbon atoms.

Abstract: Provided are crystalline forms of O-desmethylvenlafaxine fumarate, methods for their preparation, and pharmaceutical compositions thereof.

Abstract: The invention relates to gemini surfactants of formula IA wherein A is a core derived from an organic polyhydroxy compound; R1 and R2 are each independently a hydrophobic group; and R3 and R4 are each independently a surfactant head group. Such surfactants can be used as components of fluids used in the petroleum industry or used in formulating cleansing compositions or detergent compositions.

Abstract: The present invention relates to oral pharmaceutical products which are useful for binding phosphorus in ingesta, and inhibiting absorption of phosphorus from the gastrointestinal tract of subjects. A method for binding phosphorus in ingesta and inhibiting its absorption from the gastrointestinal tract is also provided. The pharmaceutical products and methods of the present invention are particularly useful in the treatment of hyperphosphatemia of chronic uremia and reducing serum phosphorus levels in patients requiring such therapy.

Abstract: The invention relates to an improved method for releasing an organic acid, preferably a carbon, sulfone or phosphone acid, particularly an alpha or beta hydroxycarbon acid, from the ammonia salt thereof by releasing and removing ammoniac and simultaneous extraction of the released acid, having an amine as a suitable extraction means from the aqueous phase. This method corresponds to a reactive extraction. The reactive extraction of an organic acid from the aqueous ammonia salt solution thereof can be significantly improved by the use of a strip medium or carrier gas, such as nitrogen, air, water vapor or inert gases such as argon. The released ammoniac is removed from the aqueous solution by the continuous gas flow and can be resupplied into a production process. The free acid can be obtained by a method such as distillation, rectification, crystallization, reextraction, chromatography, adsorption or by a membrane method from the extraction means.

Abstract: The present invention relates generally to the use of plants as bioreactors for the production of molecules having useful properties such as inter alia polymers, metabolites, proteins, pharmaceuticals and nutraceuticals. More particularly, the present invention contemplates the use of grasses, and even more particularly C4 grasses, such as sugarcane, for the production of a range of compounds such as, for example, polyhydroxyalkanoates, pHBA, vanillin, indigo, adipic acid, 2-phenylethanol, 1,3-propanediol, sorbitol, fructan polymers and lactic acid as well as other products including, inter alia, other plastics, silks, carbohydrates, therapeutic and nutraceutic proteins and antibodies. The present invention further extends to transgenic plants and, in particular, transgenic C4 grass plants, capable of producing the compounds noted above and other products, and to methods for generating such plants.

Abstract: The present invention provides a method of manufacturing a highly pure ammonium succinate solution including the steps of (A) producing calcium succinate trihydrate by crystallization fermentation of a microorganism; (B) converting calcium succinate trihydrate to calcium succinate monohydrate by transition crystallization; (C) separating the calcium succinate monohydrate crystals; (D) substituting the calcium salt in the calcium succinate monohydrate with ammonium salt resulting in an ammonium succinate solution; and (E) removing the solid calcium carbonate from the ammonium succinate solution.

Abstract: A method for decomposing N2O is described. The method uses, as a catalyst, an oxide based on cerium and lanthanum, which further includes at least one oxide of an element chosen from zirconium and rare earths other than cerium and lanthanum. This catalyst is stable, enabling it to be used at high temperatures.

Abstract: The present invention relates to salts, polymorphs and hydrates of 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.

Abstract: The present invention discloses a co-crystal compound of optical devices. The co-crystal compound is crystallized out with hydrogen bonding by a temperature fluctuation method after mixing small organic molecules without optoelectronic properties and organic molecules having heterocyclic rings with optoelectronic properties. The photoluminescence (PL) intensity of this hydrogen-bonded co-crystal compound according to the present invention can vary with a variety of the small organic molecules without optoelectronic properties, so as to modulate the PL intensity.

Abstract: This disclosure relates to a crystalline form of O-desmethylvenlafaxine and a process for its preparation. The disclosed crystalline form of O-desmethylvenlafaxine can be used for the manufacture of pharmaceutical compositions for the treatment of depression.

Abstract: The invention relates to a method for producing a biodegradable molded part, comprising: providing a binding agent which contains a lyzable biopolymer; forming a molded part from the binding agent, wherein the time stability of the molded part to biological lysis is set by at least one of the following measures: adding a pulverized inorganic solid matter in a proportion of 5% to 85% of the mass of the binding agent before forming the molded part; thawing at least one of the surfaces of the molded part using a chemical or biological method such that the surface has a structuring in the range between 1 nm and 10 ?m. The invention further relates to an accordingly produced molded part.

Abstract: The present invention provides a microorganism useful for biologically producing 3-hydroxypropionic acid from a fermentable carbon source. Further, the microorganism comprises disruptions in specified genes and alterations in the expression levels of specified genes that are useful in a higher yielding process to produce 3-hydroxypropionic acid, compositions comprising renewably sourced 3-hydroxypropionic acid provided by said microorganism, and industrial relevant products made using such renewably sourced 3-hydroxypropionic acid.

Abstract: Provided herein are methods of decreasing a level of kynurenic acid in a cell and of treating a pathophysiological condition in a subject associated with an increase in kynurenic acid in a subject. In these methods the inhibitory action of dicarboxylic acids or derivatives or analogs thereof are effective to inhibit activity of kynurenine aminotransferase II. Also provided is a method of screening for potential inhibitory compounds for kynurenine aminotransferase II. The dicarboxylic acids or derivatives or analogs thereof may have the structural formula, where R1 is H, NH2 or NHCH3, R2 is H or CH3, n is 0 to 14, and X is —COOH, CH2OH, —PO3H2, —SO3H, or —SO3H; or a pharmacologically acceptable salt.

Abstract: A process for the oxidation of alcohol and/or aldehyde groups with a peroxo compound in the presence of a heterogeneous rhenium based catalyst, and a co-catalyst. The process of the invention may, for example, be applied to the manufacture of maleic acid which can be dehydrated to lead to maleic anhydride.

Abstract: The present invention provides crystalline and amorphous salts of O-desmethylvenlafaxine and processes for preparing said salts of O-desmethylvenlafaxine. The present invention further provides pharmaceutical compositions comprising said salts of O-desmethylvenlafaxine.

Abstract: The present invention relates to nucleotide sequences encoding polypeptides with cis-aconitic decarboxylase activity, the cells transformed with such nucleotide sequences, preferably fungal or plant cells, and to methods wherein such transformed cells are use for the production of itaconic acid.

Abstract: The present invention is intended to provide a process capable of efficiently producing highly purified succinic acid from an alkali metal succinate by a simple separation and purification process. The process for producing succinic acid in the present invention comprises (1) the step to add sulfuric acid into a solution containing an alkali metal succinate, (2) the step to precipitate and remove the crystal of an alkali metal sulfate from said solution, and (3) the step to precipitate and recover the crystal of succinic acid. The removal of the crystal of an alkali metal sulfate in the step (2) is performed by a solid-liquid separation in a state that the crystal of alkali metal sulfate is precipitated by concentrating and heating the solution that is obtained by adding sulfuric acid in the step (1) and succinic acid is dissolved in the solution.

Abstract: Herein are disclosed adducts of amines and polycarboxylic acids, and methods of making such adducts. Such adducts can be used to remove cyanogen chloride. Also disclosed are methods of providing such adducts on supports to form filter media. Also disclosed are methods of combining such filter media with catalysts and/or with porous polymeric webs to form filter systems.

Abstract: Methods for extracting molecules of fulvic acid from a humus material such as oxidized lignite are disclosed. The humus material is mixed with water to solubilize at least some of the fulvic acid molecules. A first filtration apparatus (which may be an ultrafiltration apparatus) may be used to separate at least some of the solubilized fulvic acid molecules from the humin and at least some of the humic acid molecules. A second filtration apparatus (which may be an ultrafiltration apparatus or a nanfiltration apparatus) may be used to then separate the fulvic acid molecules from most of the water and any remaining impurities. A digestion step may also be carried out where microorganisms are brought into contact with the mixture in the presence of oxygen in order to oxidize any unoxidized organic compounds in the humus material. Iron and aluminum may be precipitated and removed by the addition of a phosphate to improve the purity of the end-product.

Abstract: Embodiments of the present invention are directed to reusable, length-adjustable nanoscale tethers that can be incorporated into a variety of different sensors and other electrical, electro-mechanical, electro-optical-mechanical, and optical-mechanical devices. An optionally reusable, length-adjustable nanoscale tether that represents one embodiment of the present invention comprises a binding-structure component, having a substrate-anchor subcomponent and a binding-adapter binding domain, and a binding adaptor that binds to the binding-adapter binding domain and that has a target-binding subcomponent that binds to a target molecule, target particle, or other target entity. The binding-adapter binding domain can be positioned at different distances from the substrate anchor within the binding-structure component so that the distance between a bound target and a sensor substrate can be precisely controlled.

Abstract: Methods and compositions are provided for the reduction of fouling of objects present in marine environments. The methods and compositions include anticoagulants, such as, for example, glycosaminoglycans, coumarin-type molecules, metal chelators, plasminogen activators and platelet inhibitors. The methods include reducing marine fouling, comprising incorporating an anticoagulant compound into a marine coating. In addition, the methods include identifying compounds useful for reducing marine fouling, comprising measuring either blood coagulation or barnacle cement polymerization in the presence and absence of the compound, wherein a reduction in the blood coagulation or the barnacle cement polymerization in the presence of the compound identifies the compound as useful for reducing marine fouling. The coagulation or the polymerization can be measured by a serine protease activity or a transglutaminase activity.

Abstract: The present invention relates to a method for continuously preparing cyclohexanone from phenol making use of a catalyst comprising at least one catalytically active metal selected from platinum and palladium comprising hydrogenating phenol to form a product stream comprising cyclohexanone and unreacted phenol; separating at least part of the product stream, or at least part of the product stream from which one or more components having a lower boiling point than cyclohexanone have been removed, into a first fraction comprising cyclohexanone and a second fraction comprising phenol and cyclohexanol, using distillation; separating the second fraction into a third fraction, rich in cyclohexanol, and a fourth fraction, rich in phenol, using distillation;—subjecting at least part of the fourth fraction to a further distillation step, thereby forming a fifth fraction and a sixth fraction, wherein the fifth fraction is enriched in phenol compared to the sixth fraction, and wherein the sixth fraction comprises side-pr

Abstract: A PEPCK inhibitor can include identifying a molecule that has a size capable of fitting into and interacting with the PEPCK binding site and at least one of the following: (a) a first terminal substituent having co-planar atoms acting as metal ligands to the active site metal ion PEPCK; (b) at least one of an atom or substituent at positions 2 or 3 from the first terminal substituent includes a neutral carbon center or include an oxygen, sulfur, selenium, or other atom with similar physiochemical properties; (c) at least one of an atom or substituent at positions 2 or 3 from the first terminal substituent is devoid of an electropositive atom or substituents; or (d) a second terminal substituent opposite of the first terminal substituent, said second terminal substituent having an atom that is a hydrogen boding acceptor and/or is negatively charged.

Abstract: The present invention relates to an acid salt of tolterodine with superior stabililty and useful as a transdermal drug delivery system. More specifically, the present invention relates to a novel acid salt of tolterodine with superior stabililty to the conventional acid salts of tolterodine, which is useful as a pharmaceutical composition for the treatment of overactive bladder and can be formulated into a transdermal drug delivery system.

Abstract: The present invention generally relates to processes for the chemocatalytic conversion of a pentose source to a glutaric acid product. The present invention includes processes for the conversion of pentose to a glutaric acid product via pentaric acid or derivatives thereof. The present invention also includes processes comprising the catalytic oxidation of pentose to pentaric acid and catalytic hydrodeoxygenation of pentaric acid or derivatives thereof to a glutaric acid product.

Abstract: The present invention generally relates to processes for the chemocatalytic conversion of a glucose source to an adipic acid product. The present invention includes processes for the conversion of glucose to an adipic acid product via glucaric acid or derivatives thereof. The present invention also includes processes comprising catalytic oxidation of glucose to glucaric acid or derivative thereof and processes comprising the catalytic hydrodeoxygenation of glucaric acid or derivatives thereof to an adipic acid product. The present invention also includes products produced from adipic acid product and processes for the production thereof from such adipic acid product.

Abstract: The invention relates to a method for producing ?/?-unsaturated dicarboxylic acids and the corresponding saturated dicarboxylic acids, whereby the corresponding cycloalkene and acrylic acid are reacted with a ruthenium catalyst by way of a metathesis reaction at high substrate concentrations until the reaction takes place in substance, the resulting dicarboxylic acid being precipitated.

Abstract: The invention provides compositions and methods for ameliorating, treating, reversing or preventing pathology or inflammation in the central nervous system (CNS), or the brain, caused or mediated by NFkB, IL-6, IL-6-R, NADPH oxidase (Nox), and/or superoxide and/or hydrogen peroxide production by a NADPH oxidase, including for example ameliorating, treating, reversing or preventing schizophrenia, psychosis, delirium, e.g., post-operative delirium, drug-induced psychosis, psychotic features associated with frailty syndrome (FS), aging, depression, dementias; traumatic war neurosis, post traumatic stress disorder (PTSD) or post-traumatic stress syndrome (PTSS), Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's Disease), and/or Multiple Sclerosis (MS). The invention also provides methods for purifying a C60 fullerene, C3 (tris malonic acid C60) or malonic acid derivatives.

Abstract: A process for preparing tetracarboxylic acids of the general formula I or salts thereof, wherein at least one compound of the general formula II a or II b (a) is first reacted with at least one epoxidation reagent and (b) then oxidized with nitric acid or at least one nitrogen oxide, where the variables are defined as follows: R1, R2 are the same or different and are selected from hydrogen, phenyl and C1-C10-alkyl.

Abstract: The present invention is directed to two new polymorph Form V and Form F of desvenlafaxine succinate, to processes of their preparations, pharmaceutical composition comprising such materials and their use in therapy. Form V is prepared from recrystallizing desvenlafaxine succinate in a mixture of tetrahydrofuran and ethanol. Form F is obtained from recrystallization of desvenlafaxine succinate in a mixture of cyclohexane and polar solvents such as ethanol, THF, methanol or isopropyl alcohol.

Abstract: Disclosed herein are a novel dicarboxylic acid salt of N,N-dimethylimidodicarbonimidic diamide, a preparation method thereof and a pharmaceutical composition comprising the same. More specifically, disclosed herein are a novel dicarboxylic acid salt of N,N-dimethylimidodicarbonimidic diamide, a crystalline acid addition salt prepared by allowing N,N-dimethylimidodicarbonimidic diamide to react with a specific dicarboxylic acid, which has improved physical and chemical properties including solubility, stability, non-hygroscopicity and anti-adhesive properties, and low toxicity, and thus is very effective in the prevention and treatment of not only diabetes and its complications in patients with so-called metabolic syndromes, in which diabetes, obesity, hyperlipidemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndromes, etc.